JP2013529210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529210A5 JP2013529210A5 JP2013511232A JP2013511232A JP2013529210A5 JP 2013529210 A5 JP2013529210 A5 JP 2013529210A5 JP 2013511232 A JP2013511232 A JP 2013511232A JP 2013511232 A JP2013511232 A JP 2013511232A JP 2013529210 A5 JP2013529210 A5 JP 2013529210A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- halogen
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34568310P | 2010-05-18 | 2010-05-18 | |
| US61/345,683 | 2010-05-18 | ||
| PCT/US2011/036367 WO2011146324A1 (en) | 2010-05-18 | 2011-05-13 | Spiro isoxazoline compounds as sstr5 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529210A JP2013529210A (ja) | 2013-07-18 |
| JP2013529210A5 true JP2013529210A5 (OSRAM) | 2014-06-26 |
Family
ID=44991994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511232A Withdrawn JP2013529210A (ja) | 2010-05-18 | 2011-05-13 | Ｓｓｔｒ５アンタゴニストとしてのスピロイソオキサゾリン化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20130040978A1 (OSRAM) |
| EP (1) | EP2571356A4 (OSRAM) |
| JP (1) | JP2013529210A (OSRAM) |
| AR (1) | AR081401A1 (OSRAM) |
| AU (1) | AU2011256444B2 (OSRAM) |
| CA (1) | CA2799414A1 (OSRAM) |
| TW (1) | TW201200524A (OSRAM) |
| WO (1) | WO2011146324A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2605658B1 (en) | 2010-08-18 | 2016-03-23 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| JP2015525223A (ja) | 2012-06-14 | 2015-09-03 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 動物有害生物を駆除するための置換３−ピリジルチアゾール化合物および誘導体を使用する有害生物防除方法 |
| FR3000064A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes |
| EP2970331B1 (en) | 2013-03-14 | 2017-05-17 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists |
| CN105814064A (zh) * | 2013-12-17 | 2016-07-27 | 默沙东公司 | 作为胆固醇酯转运蛋白的抑制剂的稠合双环异噁唑啉类 |
| CN104945416B (zh) * | 2014-03-24 | 2017-11-17 | 中国科学院上海药物研究所 | 一类螺异噁唑啉衍生物、其制备方法及医药用途 |
| JPWO2015146561A1 (ja) * | 2014-03-26 | 2017-04-13 | 住友精化株式会社 | 臭化芳香族エステル化合物の製造方法 |
| US10011572B2 (en) | 2014-07-29 | 2018-07-03 | Merck Sharp & Dohme Corp. | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
| TW201712012A (zh) | 2015-06-16 | 2017-04-01 | 美國禮來大藥廠 | ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物 |
| US10538490B2 (en) | 2016-10-25 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN110177773B (zh) | 2017-01-26 | 2023-08-25 | 勃林格殷格翰国际有限公司 | 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途 |
| CN110248929B (zh) | 2017-01-26 | 2023-05-12 | 勃林格殷格翰国际有限公司 | 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途 |
| WO2018170284A1 (en) | 2017-03-16 | 2018-09-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| WO2019157458A1 (en) | 2018-02-12 | 2019-08-15 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| JP7431813B2 (ja) | 2018-09-18 | 2024-02-15 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチンモジュレーターとその使用 |
| TWI841768B (zh) | 2019-08-14 | 2024-05-11 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| AR120652A1 (es) * | 2019-12-03 | 2022-03-09 | Kallyope Inc | Antagonistas de sstr5 |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN117043149A (zh) | 2021-02-17 | 2023-11-10 | 克林提克斯医药股份有限公司 | 促生长素抑制素调节剂的结晶形式 |
| CN115215787A (zh) * | 2021-04-19 | 2022-10-21 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其用途 |
| CN116354961B (zh) * | 2021-12-27 | 2025-07-25 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其药物组合物及用途 |
| CN114230552B (zh) * | 2021-12-29 | 2023-11-03 | 江苏广域化学有限公司 | 三氟甲氧基二苯并噻吩、其制备方法及相关中间体的制备方法 |
| US20240254106A1 (en) | 2022-12-13 | 2024-08-01 | Crinetics Pharmaceuticals, Inc. | Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof |
| CN115819186B (zh) * | 2023-02-14 | 2023-05-16 | 广东银珠医药科技有限公司 | 一种3,5-二氯苯甲醇的新型制备方法 |
| TWI890384B (zh) | 2023-03-27 | 2025-07-11 | 日商思可海雅藥品股份有限公司 | Sstr5拮抗劑之用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5939418A (en) * | 1995-12-21 | 1999-08-17 | The Dupont Merck Pharmaceutical Company | Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors |
| AU6780398A (en) * | 1997-03-28 | 1998-10-22 | Du Pont Merck Pharmaceutical Company, The | Heterocyclic integrin inhibitor prodrugs |
| DE102005044813A1 (de) * | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| JP4855468B2 (ja) * | 2005-09-02 | 2012-01-18 | エフ．ホフマン−ラ ロシュ アーゲー | ベンゾオキサゾール、オキサゾロピリジン、ベンゾチアゾール及びチアゾロピリジン誘導体 |
| CA2626628A1 (en) * | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type iv inhibitors |
-
2011
- 2011-05-13 EP EP11783995.1A patent/EP2571356A4/en not_active Withdrawn
- 2011-05-13 CA CA2799414A patent/CA2799414A1/en not_active Abandoned
- 2011-05-13 WO PCT/US2011/036367 patent/WO2011146324A1/en not_active Ceased
- 2011-05-13 AU AU2011256444A patent/AU2011256444B2/en not_active Expired - Fee Related
- 2011-05-13 US US13/641,767 patent/US20130040978A1/en not_active Abandoned
- 2011-05-13 JP JP2013511232A patent/JP2013529210A/ja not_active Withdrawn
- 2011-05-16 TW TW100117097A patent/TW201200524A/zh unknown
- 2011-05-17 AR ARP110101689A patent/AR081401A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013529210A5 (OSRAM) | ||
| JP2013537203A5 (OSRAM) | ||
| JP2016503797A5 (OSRAM) | ||
| JP2009533410A5 (OSRAM) | ||
| JP2011513305A5 (OSRAM) | ||
| JP2009263394A5 (OSRAM) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2014526500A5 (OSRAM) | ||
| JP2010502730A5 (OSRAM) | ||
| JP2014511891A5 (OSRAM) | ||
| JP2014504646A5 (OSRAM) | ||
| JP2012092103A5 (OSRAM) | ||
| JP2014530900A5 (OSRAM) | ||
| JP2015505296A5 (OSRAM) | ||
| JP2014511892A5 (OSRAM) | ||
| JP2016505614A5 (OSRAM) | ||
| JP2016506960A5 (OSRAM) | ||
| JP2013505969A5 (OSRAM) | ||
| JP2011521911A5 (OSRAM) | ||
| JP2014507464A5 (OSRAM) | ||
| JP2016505637A5 (OSRAM) | ||
| JP2013540712A5 (OSRAM) | ||
| JP2017508782A5 (OSRAM) | ||
| JP2014507477A5 (OSRAM) | ||
| WO2010003624A3 (en) | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |